Treating activated regulatory T cells with pramipexole protects human dopaminergic neurons from 6-OHDA-induced degeneration.
Guevara?Salinas, A., Netzahualcoyotzi, C., Álvarez?Luquín, D. D., Pérez?Figueroa, E., Sevilla?Reyes, E. E., Castellanos?Barba, C., Vega?Ángeles, V. T., Terán?Dávila, E., Estudillo, E., Velasco, I., & Adalid?Peralta, L. (2024). Treating activated regulatory T cells with pramipexole protects human dopaminergic neurons from 6?OHDA?induced degeneration. CNS Neuroscience & Therapeutics, 30(8). Portico. https://doi.org/10.1111/cns.14883
Parkinson's disease (PD) is a chronic neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, which promotes a sustained inflammatory environment in the central nervous system. Regulatory T cells (Tregs) play an important role in the control of inflammation and might play a neuroprotective role. Indeed, a decrease in Treg number and function has been reported in PD. In this context, pramipexole, a dopaminergic receptor agonist used to treat PD symptoms, has been shown to increase peripheral levels of Treg cells and improve their suppressive function. The aim of this work was to determine the effect of pramipexole on immunoregulatory Treg cells and its possible neuroprotective effect on human dopaminergic neurons differentiated from human embryonic stem cells.